A5024385469- Growth Hormone and Insulin-like Growth Factors
- Pituitary Gland Disorders and Treatments
- Adrenal and Paraganglionic Tumors
- Thyroid Disorders and Treatments
- Adrenal Hormones and Disorders
- Diet and metabolism studies
- Hormonal Regulation and Hypertension
- Neuroendocrine Tumor Research Advances
- Cancer, Hypoxia, and Metabolism
- Stress Responses and Cortisol
- Cerebrovascular and genetic disorders
- Birth, Development, and Health
- CAR-T cell therapy research
- Angiogenesis and VEGF in Cancer
- Melanoma and MAPK Pathways
- Pancreatic function and diabetes
- Apelin-related biomedical research
- TGF-β signaling in diseases
- Sympathectomy and Hyperhidrosis Treatments
- Infant Nutrition and Health
- Myasthenia Gravis and Thymoma
- Amino Acid Enzymes and Metabolism
- Sarcoma Diagnosis and Treatment
- Neurofibromatosis and Schwannoma Cases
- Metabolism, Diabetes, and Cancer
University of Oklahoma Health Sciences Center
2023-2024
Novartis (United States)
2020
Neurological Surgery
1997-2017
University of Virginia Health System
2003-2017
University of Virginia
1993-2015
Charlottesville Medical Research
1989-2001
Harvard University
1996
U.S. National Science Foundation
1996
Foundation Center
1996
University of Chicago
1990
The results of transsphenoidal surgery as initial therapy for GH-secreting pituitary adenomas in 57 acromegalic patients were analyzed retrospectively. Patients with prior or radiation excluded from the study. Three different criteria used to define remission: glucose-suppressed (nadir) GH less than 1.0 μg/liter, a normal sex- and age-adjusted IGF-I level, postoperative random levels 2.5 μg/liter less. Additionally, we neuropathological data, including immunohistochemistry ultrastructural...
In November 2003, the Pituitary Society and European Neuroendocrine Association sponsored a consensus workshop in Seville to address challenging issues medical management of acromegaly. Participants comprised 70 endocrinologists neurosurgeons with international expertise managing patients All participants participated proceedings, final document written by scientific committee reflects opinion interactive deliberations. The meeting was supported an unrestricted educational grant from Ipsen....
Pulses of growth hormone (GH) release in acromegaly may arise from hypothalamic regulation or random events intrinsic to adenomatous tissue. To distinguish between these possibilities, serum GH concentrations were measured at 5-min intervals for 24 h acromegalic men and women with active (n = 19) inactive 9) disease normal young adults the fed 20) fasted 16) states. Daily secretion rates, calculated by deconvolution analysis, greater patients than (P < 0.05) but not subjects. Significant...
Dopamine agonist administration is the primary therapy for macroprolactinomas, but bromocriptine only agent approved in United States. Its use limited by a high incidence of side effects, short duration action, and lack effectiveness some patients. Cabergoline long-acting dopamine specific D2 receptor that more effective better tolerated than women with microadenomas or idiopathic hyperprolactinemia. However, experience cabergoline treatment patients macroadenomas limited. We report first...
Growth hormone (GH) secretory patterns were studied in a patient with ectopic growth releasing factor (GRF) secretion and normal men given continuous infusions of human (1-40)-OH (hGRF-40). In the GRF secretion, GH was pulsatile despite continuously elevated immunoreactive levels. To determine if is maintained subjects, we administered to six healthy young vehicle or hGRF-40, 2 ng/kg per min, for 24 h gave supramaximal intravenous bolus dose 3.3 micrograms/kg, after 23.5 infusion. hGRF-40...
The time course of spontaneous growth hormone (GH) secretion was studied in 12 normal men by analyzing serum GH concentrations measured blood collected at 5-min intervals over 24 h with a multiple-parameter deconvolution model to simultaneously resolve endogenous secretory and clearance rates. Twenty-four-hour profiles were accounted for an average +/- 1.2 (SE) discrete bursts having mean half-duration (duration half-maximal amplitude) 25 2.3 min, indicating that 95% daily occurred 8.8 h....
Serum cortisol concentrations are increased in fasted or malnourished human subjects. The dynamic mechanisms underlying this adaptive response have been investigated eight normal men by analyzing serum measured blood obtained at 5-min intervals over 24 h on a control (fed) day and the fifth of fast (water only) assigned randomized order. A multiple parameter deconvolution method was used to simultaneously resolve endogenous secretion half-life. Five days fasting induced 1.8-fold increase...
In the male rodent and primate, fasting or severe caloric restriction significantly decreases serum testosterone concentrations, putatively via inducing secondary hypogonadotrophism. To clarify this presumptive pathophysiology, we have used: 1) a high sensitivity immunoradiometric assay, which correlates well with an in vitro Leydig cell bioassay of LH; 2) blood sampling every 5 min for 24 h basally 10 3 after GnRH injection before 5-day (water only) fast eight healthy young men; 3)...
A pharmacokinetic-pharmacodynamic study of a long-acting GH [Nutropin Depot; somatropin (rDNA origin) for injectable suspension] was performed in 25 patients with adult deficiency. Single doses 0.25 mg/kg and 0.5 mg/kg, based on ideal body weight, were administered sc. After either dose, serum concentrations rose rapidly both sexes. In men, the lower dose maintained IGF-I levels within 1 sd mean age sex 14–17 d; higher raised 2 above mean. most women, all whom receiving oral estrogen, did...
Administration of human pancreatic tumor growth hormone (GH) releasing factor (hpGRF[1-40]) as a single injection to normal subjects stimulates the secretion GH in dose-responsive manner. In present studies, hpGRF(1-40) was infused graded stepwise manner over 6-h period order determine whether secretory response would be sustained. Normal adult males received four consecutive 90-min infusions at doses 1, 3.3, 10, and 33 ng/kg per min, preceded followed by saline infusion; plasma responses...
The metabolic clearance rate (MCR) and plasma disappearance (t1/2) of human pancreatic tumor growth hormone releasing factor [hpGRF(1-40)] was determined in normal adult male subjects by single injection constant infusion techniques. Single injections 1, 3.3, 10 micrograms/kg hpGRF(1-40) were administered intravenously, immunoreactive (IR) GRF levels measured during the subsequent 180 min, biexponential curve analysis performed. Graded, dose-constant infusions at rates 10, 33 ng/kg per min...
Growth-hormone-releasing hormone (GHRH, somatoliberin) is the hypothalamic peptide that specifically stimulates synthesis and release of growth (GH, somatotropin) by somatotrope cells anterior pituitary gland. GHRH last classically postulated hormones to be characterized, synthesized, used in clinical medicine. In this review GHRH, I discuss discovery characterization peptide, its role regulation GH secretion, use pathological states excess deficiency. The two most clinically useful aspects...
Introduction Cerebrovascular pathologies contribute to cognitive decline during aging, leading vascular impairment and dementia (VCID). Levels of circulating insulin-like growth factor 1 (IGF-1), a vasoprotective hormone, decrease aging. Decreased IGF-1 in animal models leads the development VCID-like symptoms, but cellular mechanisms underlying IGF-1-deficiency associated aged cerebrovasculature remain poorly understood. Here, we test hypothesis that smooth muscle cells (VSMCs) play an...